Glythera relocated to Newcastle-upon-Tyne in 2012, following investment from IP Group and the Finance for Business North East Technology Fund which underpinned the commercialisation of its core, enabling technology platforms.
Glythera is an emerging biotechnology company focused on developing antibody-based therapies for the treatment of cancer as well as broader based therapeutics.
Our main goal is to develop effective therapies to improve patients’ lives. Our mission is to enable improved clinical regimes through creation of the next generation of safe, efficacious biotherapeutic products in the oncology and therapeutics markets. With substantial experience and expertise in bioprocessing and chemistry development, we have a proven track record of supporting programs centred on our core technologies - PermaLink™ and PermaCarb™.